<DOC>
	<DOCNO>NCT01384461</DOCNO>
	<brief_summary>This observational study evaluate safety , tolerability efficacy RoActemra/Actemra ( tocilizumab ) combination methotrexate patient moderate severe rheumatoid arthritis . Data collect 12 month patient initiated treatment RoActemra/Actemra ( 8 mg/kg intravenously every 4 week ) methotrexate ( weekly dose discretion physician ) .</brief_summary>
	<brief_title>An Observational Study RoActemra/Actemra ( Tocilizumab ) Combination With Methotrexate Patients With Rheumatoid Arthritis ( ACTIVATE )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis RoActemra/Actemra treatment initiate rheumatologist Arthritis Center ( 2 month prior study entry ) History severe allergic anaphylactic reaction know hypersensitivity component drug Active , severe infection history recurrent clinically significant infection Pregnancy Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) baseline visit Methotrexate intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>